Alvotech's Entyvio Biosimilar Candidate (AVT80) Achieves Positive Pivotal Study Results

summarizeSummary

Alvotech announced positive top-line results from a pivotal pharmacokinetic study for AVT80, its biosimilar candidate to the $6.4 billion drug Entyvio, meeting all primary endpoints and paving the way for regulatory submissions.

check_boxKey Events

• Positive Pivotal Study Results

  AVT80, a biosimilar candidate to Entyvio (vedolizumab), met all primary endpoints in its pivotal pharmacokinetic study, demonstrating PK similarity, safety, tolerability, and immunogenicity.

• Path to Regulatory Submissions

  The successful study allows Alvotech to advance towards regulatory submissions for both subcutaneous (AVT80) and intravenous (AVT16) formulations of the biosimilar.

• Targeting a Blockbuster Market

  Entyvio, the reference product, generated approximately $6.4 billion in global net revenues in 2025, highlighting the significant market opportunity for Alvotech's biosimilar.

auto_awesomeAnalysis

This announcement of positive top-line results from a pivotal pharmacokinetic study for AVT80, a biosimilar candidate to Entyvio, significantly de-risks Alvotech's pipeline. Entyvio generated approximately $6.4 billion in global net revenues in 2025, making its biosimilar a potentially major revenue driver for Alvotech. Meeting all primary endpoints in this pivotal study allows the company to proceed towards regulatory submissions for both subcutaneous (AVT80) and intravenous (AVT16) formulations, marking a critical step towards commercialization. This positive development follows a series of recent strategic moves, including a major licensing agreement, significant insider share acquisitions, and a new loan facility, collectively strengthening the company's position.